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New diagnostic tests for enteric fever are urgently needed to assist with timely
antimicrobial treatment of patients and to measure the efficacy of prevention measures
such as vaccination. In a novel translational approach, here we use two recently
developed controlled human infection models (CHIM) of enteric fever to evaluate an
antibody-in-lymphocyte supernatant (ALS) assay, which can detect recent IgA antibody
production by circulating B cells in ex vivo mononuclear cell culture. We calculated the
discriminative ability of the ALS assay to distinguish diagnosed cases in the two CHIM
studies in Oxford, prior to evaluating blood culture-confirmed diagnoses of patients
presenting with fever to hospital in an endemic areas of Kathmandu, Nepal. Antibody
responses to membrane preparations and lipopolysaccharide provided good sensitivity
(>90%) for diagnosing systemic infection after oral challenge with Salmonella Typhi or
S. Paratyphi A. Assay specificity was moderate (∼60%) due to imperfect sensitivity of
blood culture as the reference standard and likely unrecognized subclinical infection.
These findings were augmented through the translation of the assay into the endemic
setting in Nepal. Anti-MP IgA responses again exhibited good sensitivity (86%) but poor
specificity (51%) for detecting blood culture-confirmed enteric fever cases (ROC AUC
0.79, 95%CI 0.70–0.88). Patients with anti-MP IgA ALS titers in the upper quartile
exhibited a clinical syndrome synonymous with enteric fever. While better reference
standards are need to assess enteric fever diagnostics, routine use of this ALS assay
could be used to rule out infection and has the potential to double the laboratory detection
rate of enteric fever in this setting over blood culture alone.
Keywords: enteric fever, Salmonella Typhi, Salmonella Paratyphi A, diagnostic test, antibody-in-lymphocyte
supernatant assay, febrile illness, resource-limited settings, bacteremia
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INTRODUCTION
Infections due to Salmonella enterica serovars Typhi (S. Typhi)
and Paratyphi A (S. Partayphi A) affect ∼27 million individuals
each year, although accurate disease burden calculation is
hindered by inadequate diagnostics (Buckle et al., 2012; Wain
et al., 2015). New approaches are needed to improve these
estimates and to allow timely, accurate discrimination of enteric
fever from other causes of non-specific febrile disease (Parry
et al., 2011; Darton et al., 2014).
The most sensitive and specific assay currently available for
the diagnosis of enteric fever infection is culture of bone marrow
aspirate (Crump et al., 2015). Blood culture is more commonly
used as a reference standard, although is increasingly recognized
as a poor comparator for new diagnostic tests due to low
sensitivity (Crump et al., 2015; Storey et al., 2015). Causes of
this low sensitivity include the low level bacteremia that occurs
with the onset of clinical typhoid symptoms and the frequency
of pre-hospital antibiotic consumption in endemic areas, which
both affect the number of viable bacteria collected in each
sample. These factors are partially mitigated by collecting a larger
blood volume (∼10mL), although this is frequently impractical
especially in younger children (Wain et al., 1998; Darton et al.,
2014). Alternative methods detecting the antibody responses
using the Widal test, enzyme-linked immunosorbent assays
(ELISAs), or rapid diagnostic tests, are largely disappointing due
to cross-reactivity, low sensitivity and pre-existing immunity in
endemic settings (Parry et al., 2011; Crump et al., 2015).
Due to the lower blood volumes required and the potential
to minimize the effect of prior antimicrobial therapy, the
confirmation of enteric fever diagnosis by detection of
serologic markers is appealing. Additionally, the possibility
for multiplexing assays to target diverse Salmonella species
along with other bacterial, viral, and parasitic pathogens is a
desirable aim for most commercial diagnostic developers (Baker
et al., 2010; Chappuis et al., 2013). Among recent efforts to
improve the accuracy of serological methods for enteric fever
diagnosis has been the development of an immunodiagnostic test
utilizing antibody-in-lymphocyte supernatant (ALS) (Chang and
Sack, 2001). Exposure of Salmonella spp. to antigen presenting
cells in the gut mucosa generates gut-homing plasma B cells
that can be detected ex vivo in peripheral blood during cell
re-circulation in the reticuloendothelial system (Kirkpatrick
et al., 2005; Sheikh et al., 2009). Specifically detecting plasma
cell responses precludes the detection of pre-existing immunity,
which is common in endemic settings and confounds most
other serological approaches. It is therefore possible to detect
immunological responses to recent enteric bacterial exposure
by assaying ALS secreted by peripheral blood mononuclear cells
(PBMC).
Previous studies in Bangladesh have evaluated ALS responses
to S. Typhi specific-lipopolysaccharide (LPS), formalin
inactivated whole cell preparations, and Ty21a membrane
preparation (MP) in patients with suspected enteric fever
(Sheikh et al., 2009). While IgA and IgG ALS responses were
observed against LPS and whole cell preparations, an IgA
response only was observed against MP (“anti-MP IgA”),
indicating possible recent gut mucosa exposure specifically to
S. Typhi or S. Paratyphi A (Sheikh et al., 2009). Further clinical
evaluation suggested that anti-MP IgA responses measured in
confirmed typhoid/paratyphoid patients were 100% sensitive
and 78–97% specific and short-lived, indicating recent acute
illness rather than background cross-reactivity (Khanam et al.,
2013; Islam et al., 2016). In this prospective study we aimed to
evaluate the diagnostic performance of anti-MP IgA responses
using ALS samples collected during two human enteric fever
challenge models (S. Typhi and S. Paratyphi A) (Waddington
et al., 2014; McCullagh et al., 2015), and in an endemic enteric
fever area of Kathmandu, Nepal (Karkey et al., 2010, 2013, 2016).
MATERIALS AND METHODS
Ethics Statement
All studies were carried out in accordance with the relevant
clinical trial protocols, and the International Conference on
Harmonization (ICH) Good Clinical Practice standards. All
study participants (or their parents if aged under 18 years in
Nepal) gave written informed consent prior to enrolment, in
accordance with the Declaration of Helsinki. Illiterate signatories
were read the details of the consent form in the presence of
a literate witness who could attest to the accurate reading of
the consent and the agreement of the signatory (Nepal only).
Study protocols for the typhoid and paratyphoid CHIMs were
approved by the UK National Research Ethics Service (typhoid
challenge, 10/H0604/53; paratyphoid challenge, 14/SC/0004;
both Oxfordshire Research Ethics Committee A) and for the
Nepal field study by the Nepal Health Research Council (ref.
736) and the Oxford Tropical Ethics Committee (OxTREC, ref.
38-11).
Human Challenge Studies
Groups of healthy adult volunteers were challenged with a single
oral dose of either S. Typhi (Quailes strain) or S. Paratyphi A
(strain NVGH308) at a single site in Oxford, United Kingdom,
as previously described (Figure 1; Waddington et al., 2014;
McCullagh et al., 2015). Briefly, participants were monitored
for 14 days after oral challenge (“baseline”), at 28 days and
further time points thereafter. Typhoid/paratyphoid diagnosis
and the initiation of antimicrobial treatment was performed if
either clinical (temperature≥ 38◦C for≥12 h) or microbiological
(bacteremia) endpoints were reached, and at day 14 in all
remaining participants.
Blood for culture (10mL) was collected each day until day 14
or 96 h after typhoid diagnosis (TD) or paratyphoid diagnosis
(PD) wasmade (TD+96 h or PD+96 h), whichever was the latter;
at the TD/PD+0 h time point, 5mL was collected. Blood culture
was performed using continuous automated culture (BACTEC
FX system, BD), using standard methods (Health Protection
Agency, 2013; Waddington et al., 2014). Duration of bacteremia
was calculated as time from first culture positive to first culture
negative sample collected. ALS material was collected from
a subset of participants diagnosed with typhoid, whereas in
the subsequent paratyphoid challenge study, ALS material was
Frontiers in Microbiology | www.frontiersin.org 2 October 2017 | Volume 8 | Article 2031
Darton et al. ALS Diagnostics for Enteric Fever
collected from all challenge study participants whether diagnosed
with paratyphoid fever or not (Figure 1).
Endemic Enteric Fever Setting
In Kathmandu, Nepal, blood samples were collected
prospectively at Patan Hospital in Lalitpur Sub-Metropolitan
City (LSMC), and at the Civil Service Hospital both in the
Kathmandu Valley area of Nepal. Consenting patients aged >14
years with a clinical diagnosis of typhoid fever (including a
history of fever for ≥3 days without a focus of infection) were
enrolled. Blood samples (13mL) were collected at presentation, 7
days and 3 or 6 months later (Figure 1C). Routine blood culture
was performed at presentation using local, non-automated
culture methods; ALS assays were performed at each time
point. ALS results were not used for clinical decision-making.
Blood culture, isolation of Salmonella serovars and susceptibility
testing was performed according to previously described local
procedures (Arjyal et al., 2016).
Antibody-in-Lymphocyte Supernatant
Assay
Isolation of PBMC and harvesting of cell culture supernatant
was performed in Oxford and at Patan Hospital in-keeping
with previously described methods (Sheikh et al., 2009; Khanam
et al., 2013; Islam et al., 2016). In brief, PBMC separated
from venous blood (5mL) by density-gradient centrifugation
were re-suspended to a concentration of 1 × 107 cells/mm3
before incubation at 37◦C, 5% CO2 in tissue culture plate
wells. After 48 h, culture supernatants were harvested and
stored with protease inhibitors at −80◦C until further use.
Specific IgA and IgM isotype ALS responses to S. Typhi
LPS (L2387; Sigma, Dorset), S. Typhi flagellin (prepared in-
house by shearing, centrifugation and purification of a whole
cell preparation), S. Paratyphi A LPS (O:2; GVGH, Italy), or
membrane preparations [made in-house using the method by
Sheikh et al. (2009), from S. Typhi strain Ty21a, “MP,” or
S. Paratyphi A NVGH308, “MPN”] were measured by ELISA
at dilutions of 1:4 or 1:2, as previously described (Sheikh
et al., 2009), using goat anti-human IgA or IgM conjugated to
horseradish peroxidase (Biorad, UK). ELISA readouts from each
site were standardized; optical density readings were divided by
that of a pooled positive control serum standard, multiplied by
100 and expressed as ELISA units (Sheikh et al., 2009; Khanam
et al., 2013).
Statistical Analysis
ALS responses were log10-transformed for normalization prior
to analysis. Analysis of log-transformed ALS assay responses
from repeated sampling in challenge studies was evaluated using
mixed effects models and adjusted for challenge dose received.
Characteristics associated with maximal ALS responses were
investigated using multiple linear regression. The anti-log of
the parameter estimates from both mixed effects and linear
regression models are presented as geometric means with 95%
confidence intervals (95% CI).
As no gold-standard test for enteric fever diagnosis is available,
the following assumptions were made in determining the sample
FIGURE 1 | Study sample collection for use in evaluating ALS responses as a
diagnostic test for enteric fever. (A) Typhoid challenge study (OVG2009/10).
Groups of 20 healthy, screened, and enrolled adult participants were
challenged with either 1–5 × 103 CFU or 10–50 × 103 CFU S. Typhi Quailes
strain in a dose-escalation study. Participants were challenged by oral
ingestion at baseline (D0) and monitored by daily clinical review, routine blood
chemistry and hematology and blood culture. Typhoid diagnosis (TD) was
made based on a priori definitions of having a temperature ≥38◦C for ≥12 h
(temperature criterion) and/or having a positive blood culture with S. Typhi
(blood culture criterion). Samples for measurement of ALS responses were
collected at baseline, TD, TD+48 h, and TD+96 h. Antibiotic treatment was
initiated at TD or at D14 in all participants not reaching the typhoid diagnosis
endpoint. (B) Paratyphoid challenge study (OVG2013/07). Groups of 20
healthy, screened and enrolled adult participants were challenged with either
1–5 × 103CFU or 0.5–1 × 103CFU S. Paratyphi A strain NVGH308 in a
dose-reduction study. Participants were challenged by oral ingestion at
baseline (D0) and monitored by daily clinical review, routine blood chemistry,
and hematology and blood culture. Paratyphoid diagnosis (PD) was made
based on a priori definitions of having a temperature ≥38◦C for ≥12 h
(temperature criterion) and/or having a positive blood culture with S. Paratyphi
(blood culture criterion). Samples for measurement of ALS responses were
collected at baseline, D4, D7, D10, D14, and D28. Alternatively, in those
reaching PD, samples were collected instead at PD, PD+48 h, and PD+96 h.
Antibiotic treatment was initiated at PD or at D14 in all participants not
reaching the paratyphoid diagnosis endpoint. (C) Nepal field evaluation.
Participants were recruited from individuals presenting with fever and an illness
clinically compatible with enteric fever to either Patan Hospital or the Civil
Hospital in Patan. Blood for culture and extraction of PBMC/ALS was
collected at presentation to hospital (D0), after which antibiotic treatment for
enteric fever was given. Further samples were collected to measure ALS
responses at D7, month 3 (M3), or month 6 (M6).
size for the ALS evaluation inNepal: (i) that the true prevalence of
typhoid in febrile individuals enrolled to the study was 80%, and
(ii) that blood culture would correctly classify 50% of participants
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TABLE 1 | Oxford challenge studies: clinical parameters.
Study Typhoid challenge (N = 23) Paratyphoid challenge (N = 40)
Challenge agent, strain S. enterica serovar Typhi,
Quailes strain
S. enterica serovar Paratyphi A, strain NVGH308
Participants included in ALS
analysis (type)
Challenge and diagnosed participants only All challenged participants
Challenge dose level Low High Low Lower
Target dose 1–5 × 103 10–50 × 103 1–5 × 103 0.5–1.0 × 103
Actual dose, median [range] 1.05 × 103 [0.7–1.8] 19.8 × 103 [15.5–27.0] 2.40 × 103 [2.2–2.8] 0.91 × 103 [0.7–1.3]
Number assessed 11 12 20 20
Male sex, N (%) 11 (100) 7 (58) 10 (50) 11 (55)
Median age, yrs [range] 27 [19–41] 28 [20–44] 28 [19–49] 28 [23–50]
Attack rate, N (%) na na 12 (60) 8 (40)
Median time to diagnosis, days
[IQR]
11 [7–13] 8 [6–9] 6 [6–7] 8 [8–9]
Mode diagnosis, n(%)
Temperature criterion 6 (60) 7 (58) 1 (9) 0 (0)
Blood culture criterion 4 (40)* 5 (42) 11 (81) 8 (100)
≥1 positive blood cultures, N (%
diagnosed)
9 (90)* 10 (83) 12 (100) 8 (100)
Median duration bacteraemia,
days [IQR]
1 [1–2] 2 [1–3] 4 [2.5–5] 1 [1–4.5]
Median temperature at
diagnosis, ◦C [IQR]
37.9 [36.7–38.7] 37.8 [37.3–38.1] 37.4 [36.9–38.0] 36.9 [36.5–37.3]
Median heart rate at diagnosis,
bpm [IQR]
96 [79–109] 95 [83–104] 87 [80–92] 83 [79–89]
Typhoid symptom triad*, N (%) 11 (55) 12 (75) 6 (30) 3 (15)
*Typhoid symptom triad = fever, headache plus abdominal pain. na, not applicable.
as having enteric fever. Thus in a sample size of 100, there would
be 80% power to detect a difference in the proportion diagnosed
through blood culture and those through ALS, using McNemar’s
test and assuming a discordant pairs rate of 20% and a 15% rate
of non-evaluable samples.
We determined an a priori cut-off threshold for a positive
ALS response by taking the geometric mean of all baseline
samples (or in Nepal the month 3 or 6 result) plus three
standard deviations. Assay performance was analyzed by
receiver-operator characteristic (ROC) curves using the pROC
package in R (version 3.3.0; Robin et al., 2011), and inter-
assay agreement by the Bland-Altman method (Giavarina,
2015), implemented using the MethComp package (version 1.22;
Carstensen et al., 2013).
RESULTS
ALS Assay in a Salmonella Typhi Challenge
Study
In the controlled human infection model of typhoid fever, 21
participants ingested 1–5 × 103 CFU and 20 ingested 10–
50× 103 CFU of S. Typhi, resulting in attack rates of 55% (11/20)
and 65% (13/20), respectively (Waddington et al., 2014). ALS
material was collected from 11/11 and 12/13 of these participants
developing typhoid infection, of which 9/11 (82%) and 10/12
(83%) were confirmed by positive blood culture (Table 1).
An assessment of anti-MP IgA ALS responses in participants
developing typhoid infection demonstrated a significant increase
between baseline and TD time points (baseline to all time
points p < 0.0001; Table 2). These changes were consistent
across all time points until TD+96 h (p = 0.860), and were
observed in most participants (Figure S1). IgA ALS responses
against S. Typhi-specific LPS were comparable to those against
MP, however responses against flagellin were less pronounced
(Table 2, Figure S1). Maximal anti-MP IgA ALS responses were
significantly associated with bacteremia duration (Spearman’s
ρ = 0.42, p = 0.048) and age (Spearman’s ρ = −0.44, p = 0.038).
In multiple linear regression models, these responses were
significantly lower in older participants (geometric mean ratio,
GMR 0.95 per year, 95% CI 0.91–0.99, p = 0.023) and higher
in those with longer durations of bacteremia (GMR 1.45 per day
bacteremia, 95% CI 1.07–1.96, p= 0.020).
Anti-MP IgA ALS responses diagnostic of typhoid infection
were recorded in 11/11 (100%) and 10/12 (83%) participants who
developed typhoid infection following challenge with 103 or 104
CFU S. Typhi, respectively (Figure 2). With the study definition
of TD as the reference standard, the sensitivity of anti-IgA MP
ALS responses was 91% (95%CI 72–99%). ALS IgA responses
against LPS correlated with MP responses (r 0.99, p < 0.0001),
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TABLE 2 | Analysis of ALS responses to three antigens (MP, LPS, and flagellin) in
participants challenged with ST (baseline) and diagnosed with typhoid infection.
Geometric mean
(95% CI)
Fold change
from baseline*
(95% CI)
p* p (Type III)#
MP
Baseline 5.3 (4.9–5.8)
TD 27.3 (16.5–45.3) 5.37 (3.21–8.99) <0.0001 0.860
TD+48 h 23.5 (14.8–37.4) 4.52 (2.9–7.06) <0.0001
TD+96 h 27.7 (16.8–45.7) 5.22 (3.22–8.47) <0.0001
LPS
Baseline 6.2 (5.7–6.7)
TD 29.8 (18.0–49.3) 5.16 (3.09–8.6) <0.0001 0.873
TD+48 h 26.3 (16.7–41.4) 4.41 (2.83–6.87) <0.0001
TD+96 h 31.0 (18.8–50.9) 5.06 (3.13–8.18) <0.0001
FLAGELLIN
Baseline 11.7 (10.8–12.7)
TD 15.8 (12.1–20.6) 1.39 (1.13–1.72) 0.003 0.248
TD+48 h 15.2 (13.1–17.7) 1.31 (1.09–1.57) 0.005
TD+96 h 12.7 (10.9–14.7) 1.11 (0.91–1.35) 0.304
Output are from mixed effects models with a random intercept for each participant.
Variables for dose and visit included in the model as fixed effects. *Adjusted for challenge
dose received (high or low). #P-value testing whether change from baseline is different
across visits. TD, day of typhoid diagnosis.
were completely concordant with the diagnostic classification
(Table S1), and had acceptable inter-assay agreement (Figure S2).
In contrast, while ALS IgA responses against flagellin correlated
with MP responses, they demonstrated poor agreement and a
significant bias toward lower responses in the flagellin assay
(Figure S2). Fewer participants had flagellin IgA titers exceeding
the diagnostic threshold at time points at and after TD
(Figure 2).
ALS Assay in a Salmonella Paratyphi a
Challenge Study
In a S. Paratyphi A challenge study, 40 participants ingested either
1–5× 103 CFU or 0.5–1× 103 CFU of S. Paratyphi A, resulting in
attack rates of 12/20 (60%) and 8/20 (40%), respectively (Table 1).
All paratyphoid diagnoses were confirmed by positive blood
cultures and ALS samples were collected at baseline and at days
4, 7, 10, 14, and 28 from all participants, in addition to other time
points after paratyphoid diagnosis (PD, PD+48 h, and PD+96 h;
Figure 1).
Significant increases in ALS IgA responses against S. Paratyphi
A MP (MPN) were observed at PD time points in diagnosed
participants (all p < 0.0001) and did not change at later PD
time points (p = 0.072; Table 3). Maximal anti-MPN IgA ALS
responses against MP positively correlated with challenge dose
(Pearsons’s ρ = 0.33, p = 0.035), maximal oral temperature
(Spearman’s ρ = 0.43, p = 0.005), duration of bacteremia
(Spearman’s ρ = 0.65, p < 0.0001), and time elapsed between
challenge and diagnosis (PD only, Spearman’s ρ = −0.45,
p = 0.046). In a multiple linear regression model, the duration
of bacteremia was the only variable significantly associated with
maximal anti-MPN IgA ALS responses (GMR 1.25 per day
bacteremia, 95%CI 1.11–1.39, p < 0.0001).
In this study, anti-MPN IgA ALS responses diagnostic of
paratyphoid infection were recorded in 10/12 (83%) participants
and 8/8 (100%) participants who developed paratyphoid
infection following challenge with 1–5 × 103 or 0.5–1 × 103
CFU of S. Paratyphi A, respectively (Figure 3). This resulted
in a sensitivity of 90% (95%CI 68–99) and specificity of 60%
(95%CI 36–81) for the detection of the study-defined PD
endpoint (Table 4). Eight participants had diagnostic anti-MPN
IgA ALS responses at day 14 without reaching PD (Figure S3).
These participants were notably more symptomatic, for example,
reporting more severe (Grade 3) symptoms than other nPD
individuals (p= 0.014 Mann–Whitney U-test).
Overall, there was good agreement between the anti-MPN
and anti-LPS IgA ALS assays (Figure S4). As with the false-
positive responses identified in the anti-MPN assay, positive
anti-LPS IgA ALS responses were also observed in individuals
without PD (Figure 3 and Table S2). The AUC ROC for anti-
MPN IgA ALS responses to detect participants meeting the study
endpoint definition for PD (reference standard) was 0.85 (Figure
S5). The AUC for the anti-LPS IgA assay responses was not
significantly different (AUC 0.80, 95% CI 0.66–0.94, p = 0.255;
Figure S5).
ALS Assay in a Febrile Disease Cohort in
Kathmandu
Between June 2013 and December 2014, 177 patients presenting
with non-specific febrile illness were recruited into a prospective
diagnostics study in Nepal (Figure S6). Table 5 describes the
patient cohort (see also Table S3). Blood cultures confirmed
21/177 (12%) had S. Typhi and 14/177 (8%) had S. Paratyphi A
bacteremia. Blood for ALS measurements was collected at day 0,
day 7, and at months 3 or 6 (Figure 1). Anti-MP IgA responses
were measured at day 0 for 173/177 patients (Figure S6).
Overall, anti-MP IgA ALS responses in samples collected
on day of presentation (day 0) were significantly higher in
bacteremic patients compared with those with a sterile blood
culture (GMR bacteremia vs. no growth 1.85, 95%CI 1.55–2.21;
p < 0.0001). Further, anti-MP IgA ALS responses at day 0 were
significantly higher in S. Typhi and S. Paratyphi A culture positive
patients compared to with those with a sterile blood culture
(GMR 2.13, 95%CI 1.72–2.64, p < 0.0001 for S. Typhi; and 1.50,
1.16–1.94, p = 0.002 for S. Paratyphi A; Figure 4). There were
significant differences in ALS measurements between day 0 and
7 in all three groups, including a 9% decrease in the no growth
group (GMR day 7/day 0: 0.91, 95%CI 0.84–0.98, p = 0.018).
Larger decreases of 32 and 39% were observed in the S. Typhi
and S. Paratyphi bacteremic patients, respectively (p < 0.001,
Figure 4).
Data from convalescent samples at month 3 andmonth 6 were
combined. Anti-MP IgA ALS responses were significantly lower
at month 3/6 than day 0 in those with a positive blood culture
(p < 0.0001). In contrast, no significant change in ALS response
was observed in patients with sterile blood cultures (p = 0.202,
Figure 4 and Figure S7).
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FIGURE 2 | ALS IgA diagnostic responses to MP, LPS, and flagellin in participants diagnosed with typhoid after challenge. Low dose, 1–5 × 103CFU; High dose,
10–50 × 103CFU. “White” indicates the titer was below the diagnostic cut-off (log100.95, log101.00, and log101.28EUs for the three antigens tested, respectively).
“Gray” indicates sample not available.
ALS Assay Diagnostic Performance
Using blood culture-confirmed cases as the reference standard
and applying a diagnostic threshold cut-off of 28.8EU (derived as
described in Methods), anti-MP IgA ALS responses resulted in a
test sensitivity of 85.7% (95% CI 69.7%−95.2%) and specificity
of 51.4% (42.8–60.0%, Table 6). Further exploration of these
responses by ROC curve analysis demonstrated an AUC of 0.79
(Figure S9), indicating “fair” to “good” test accuracy (Metz, 1978).
ALS IgA MP responses using the 1:2 or 1:4 dilution resulted
in comparable ROC curves (p = 0.097) (Figure S8). There was
also was no significant difference in AUC values for MP IgM
compared to MP IgA 1:4 (p= 0.357).
While ALS demonstrated reasonable sensitivity, measured
specificity using blood culture confirmed cases as the reference
standard was poor. Amongst all patients and using a threshold
of 28.8EU for anti-MP IgA ALS, 72/177 (41%) participants had
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TABLE 3 | Analysis of ALS responses to MPN and LPS in participants challenged
with Salmonella Paratyphi A and diagnosed with paratyphoid infection.
Geometric mean
(95% CI)
Fold change
from baseline*
(95% CI)
p* p (Type III)#
MP
Baseline 7.3 (7.0, 7.6)
PD 19.2 (13.5, 27.2) 2.54 (1.76, 3.66) <0.0001 0.072
PD+48 h 17.3 (10.9, 27.4) 2.29 (1.59, 3.3) <0.0001
PD+96 h 30.5 (20.1, 46.1) 4.03 (2.8, 5.81) <0.0001
LPS
Baseline 7.2 (6.9, 7.5)
PD 15.2 (10.3, 22.5) 2.07 (1.4, 3.06) <0.0001 0.085
PD+48 h 16.7 (10.8, 25.8) 2.28 (1.54, 3.36) <0.0001
PD+96 h 27.1 (17.0, 41.0) 3.7 (2.51, 5.46) <0.0001
Output are from mixed effects models with a random intercept for each participant.
Variables for dose and visit included in the model as fixed effects. *Adjusted for challenge
dose received (high or low). #P-value testing whether change from baseline is different
across visits. PD, Day of paratyphoid diagnosis.
discordant blood culture and ALS responses. Five (6.9%) of these
participants were BC+/ALS- and 67 (63.1%) participants were
BC−/ALS+ (p < 0.0001 McNemar’s test). To further investigate
this, participants were classified as “low” responders if anti-MP
IgA ALS responses were <25th percentile (<1.39 log10EU) and
“high” responders if >75th percentile (>1.64 log10EU). Of the
79 participants falling into these quartiles, 2/36 (5.6%) in the low
and 22/42 (52.3%) in the high responder group had confirmed
S. Typhi or S. Paratyphi bacteremia (Table S4). High responders
were significantly more likely to report fever, headache and
abdominal pain (p = 0.024), and had a significantly lower white
cell count (WCC) compared to low responders (p < 0.0001).
DISCUSSION
New diagnostic tests for accurately detecting cases of enteric
fever are needed, to enable prompt appropriate treatment of
patients with antibiotics and to accurately measure the impact of
prevention strategies including vaccination. Here, we aimed to
evaluate a promising new ALS assay for use as an enteric fever
diagnostic in two recently developed controlled human infection
models (CHIM) and in an endemic setting.
Our findings from the human models suggest that detecting
IgA responses to homologous membrane preparations in ALS
sample material could be a sensitive method for detecting enteric
fever cases. As expected, ALS responses to MP and LPS were very
similar in both typhoid and paratyphoid infections, suggesting
that MP could be used as a suitable reagent in settings were
a suitable source of purified LPS is not available. Despite its
inclusion as a component of the Widal test, diagnostic responses
to flagellin during acute infection were less convincing, at least
in the settings studied here. Specificity was less easy to evaluate
in the challenge setting, where alternate causes of fever are
not anticipated during the brief two-week challenge period.
In Nepal, the sensitivity of anti-MP IgA ALS responses to
detect bacteremia-confirmed enteric fever cases from patients
presenting with non-specific febrile illness was similar to the
sensitivity observed in challenge studies, and ROC curve analysis
suggested “good” performance as a diagnostic test. Specificity was
low when using blood culture as a reference standard in Nepal.
This may be related to the low sensitivity of blood culture in this
setting, probably driven by frequent exposure to antimicrobials
prior to enrolment. With the conservative assumption that those
participants with ALS responses >75th percentile were true
enteric fever cases, as indicated by the compatible clinical features
within this group, additional use of the ALS assay in an endemic
setting may double the number of cases confirmed by blood
culture alone.
In the CHIM studies we found that the ALS assay, utilizing
IgA responses against MP, was ∼90% sensitive for detecting
challenged participants developing typhoid/paratyphoid
infection. Furthermore, these responses persisted for at least
96 h after diagnosis and resolved by day 28. Responses in both
challenge studies were strongly associated with the duration of
bacteremia, likely increasing the period of antigen presentation
and thus amplification of the immune response. In Nepal the
sensitivity of the ALS IgA MP (1:4 assay) responses for detecting
bacteremia-confirmed enteric fever patients was similar to the
challenge studies (85.7%), although lower than those observed
in previously published ALS studies which consistently reported
sensitivities of 100% (Sheikh et al., 2009; Khanam et al., 2013;
Islam et al., 2016). Reasons for higher reported sensitivity in other
studies may include younger patients, lower pre-hospitalization
antimicrobial treatment, or a greater proportion of female study
participants compared with our evaluation (Sheikh et al., 2009;
Khanam et al., 2013); all of these factors can influence either the
degree of bacteremia or the resulting immune response (Wain
et al., 1998; Dewan et al., 2013; Garcia-Gomez et al., 2013).
Our finding of <100% sensitivity in Nepal is further supported
by the results from the challenge studies, in which 2/23 and
2/40 S. Typhi and S. Paratyphi A challenged and diagnosed
participants, respectively, failed to demonstrate a diagnostic
response, despite being bacteremic. While the threshold used
was higher than that in previous studies (28.8EU vs. 10EU), this
was supported by data from assays performed in Nepal using
samples collected from several healthy controls in the UK and
in Nepal (∼20EU). As recently identified in serological surveys,
this suggests that a dynamic cut-off for assay positivity may be
required, reflecting background exposure (i.e. seroreactivity) and
disease seroprevalence.
Assay specificity was difficult to interpret from the challenge
studies; in the typhoid challenge model only diagnosed
participants were included making this incalculable. Results
from the paratyphoid challenge model suggested a relatively low
specificity of ∼60%. Notably, the majority of PD participants
were diagnosed based on blood culture criteria which, with an
assumed ∼80% sensitivity, is likely to have resulted in missed
case detection. Individuals with diagnostic ALS responses but
negative blood cultures were more symptomatic and may have
had subclinical or developing infection, which would have been
abrogated by antimicrobial therapy on day 14. Additionally, high
ALS responses may also reflect a successful immune response
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FIGURE 3 | ALS IgA responses to MPN or LPS in participants challenged with Salmonella Paratyphi A according to challenge dose level and challenge outcome. High
dose, 1–5 × 103 CFU; Low dose, 0.5–1 × 103 CFU. nPD, paratyphoid not diagnosed; PD, paratyphoid diagnosed. “White” indicates the titer was below the
diagnostic cut-off (10EU). “Gray” indicates sample not available.
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to clear S. Paratyphi from the intestinal mucosa without clinical
disease. Necessary restriction of the challenge period to 14 days
is is an important limitation to using this CHIM, especially for
evaluating serological responses. Treatment of all participants
TABLE 4 | Performance of anti-MPN IgA ALS responses as a serodiagnostic test
compared to the study paratyphoid diagnosis definition (fever and/or bacteremia).
Study paratyphoid diagnosis (%)
Yes No Total
MPN diagnostic response,
n > 9.9EU (%)
Yes 18 (45) 8 (20) 26 (60)
No 2 (5) 12 (45) 14 (40)
Total 20 (50) 20 (50) 40 (100)
LCL UCL
Sensitivity 90.0% 68.3% 98.8%
Specificity 60.0% 36.1% 80.9%
PPV 69.2% 48.2% 85.7%
NPV 85.7% 57.2% 98.2%
PPV, positive predictive value; NPV, negative predictive value. LCL, lower confidence limit;
UCL, upper confidence limit.
at day 14 was required to ensure that subclinical infection was
not missed and to minimize the risk of complications including
bowel perforation which are more frequently seen in after 3-
weeks of infection.
In Nepal, assay specificity was also relatively low at 51.4%
using the a priori method for calculating the diagnostic cut-off.
Reasons for this low measurement are likely to be multifactorial,
but strongly influenced by the use of blood-culture confirmed
cases as the reference standard. This highlights the inadequacy
of using blood culture as the reference/gold standard test with
which to evaluate newermethods. Previousmethods to overcome
this have included use of latent class analysis or a composite
diagnostic endpoint made of alternate, less effective tests (Islam
et al., 2016). While these methods demonstrate apparently high
levels of specificity for the ALS assay, febrile control populations
are often comprised of patients with non-enteric diseases that
present with features that are unlike acute enteric fever (Khanam
et al., 2013; Islam et al., 2016). In addition, previous evaluations
of the ALS method have often used the Widal test as a method
to screen for a “true negative” population, which removes any
participants with false-positive seroreactivity (Islam et al., 2016).
Of note, the low specificity of the ALS assay (51.4%) using
this cut-off threshold (28.8EU) was equivalent to that found
TABLE 5 | Nepal ALS study participant demographics and clinical characteristics.
Blood culture result S. Typhi S. Paratyphi A No growth p#
Number 21 14 142
Demographic nA Result n Result n Result
Age, median (IQR) 21 26 (17–30) 14 20 (18–26) 142 25 (19–32) 0.179
Male sex (%) 21 17 (81) 14 11 (79) 142 93 (66) 0.565
Residence (%) 19 10 130
Lalitpur 8 (42) 4 (40) 83 (64)
Kathmandu 8 (42) 4 (40) 32 (25)
Bhaktapur 1 (5) 1 (10) 6 (5)
OtherB 2 (11) 1 (10) 9 (7)
Median residence Kathmandu Valley, yrs (IQR) 6 3 (2–4) 7 2 (2–6) 60 10 (7–19) <0.0001
WATER SUPPLY
Water source (%) 19 11 137
Supply tap 10 (53) 3 (27) 89 (65)
Jar 3 (16) 7 (64) 18 (13)
Water tanker 4 (21) 0 13 (9)
Well 1 (5) 0 9 (7)
Stone spout 1 (5) 1 (9) 8 (6)
Other 0 0 4 (3)
Use water treatmentC (%) 19 9 (11.0) 11 4 (4.9) 139 69 (84.1) 0.694
CLINICAL CHARACTERISTICS
Mean illness duration (range), days 18 5.7 (2–15) 10 6.2 (3–14) 138 5.5 (2–20) 0.425
Prior antibiotics given, n (%) 9 6 (67) 3 3 (100) 91 39 (43) 0.067
Median prior antibiotic duration (IQR), days 4 3 (1–3) 2 3 (1–4) 37 3 (2–3) 0.778
Previous typhoid, n (%) 17 2 (12) 10 2 (20) 137 43 (31) 0.198
Previous typhoid vaccine, n (%) 18 0 10 0 138 2* (1) 0.814
Family member with typhoid, n (%) 18 3 (17) 11 3 (27) 136 17 (13) 0.372
An, number for which clinical data were available. BOther includes Dhading 2/159, Kavre 3/159, Other 7/159. CWater treatment, including “filtering” 51/169, “boiling” 24/169, “chlorination”
3/169, “other” 4/169. No growth includes contaminants N= 8/177 (4.5%). *Both received vaccine within 3 years prior to presentation. #Group-wise comparisons weremade by Pearson’s
chi-squared or Kruskal–Wallis tests. The p value in bold indicates that it reaches significance at the 0.05 threshold.
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FIGURE 4 | Group ALS responses in each assay condition by time point, according to blood culture result.
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TABLE 6 | Contingency table of Nepal field study anti-MP IgA ALS results (1:4
concentration) and blood-culture confirmed cases.
Bacteremia (%)
Yes No Total
ALS IgA MP 1:4
diagnostic response,
n > 28.8EU (%)
Yes 30 (17.3) 67 (38.8) 97 (56.1)
No 5 (2.9) 71 (41.0) 76 (43.9)
Total 35 (20.2) 138 (79.8) 173
LCL UCL
Sensitivity 85.7% 69.7% 95.2%
Specificity 51.4% 42.8% 60.0%
PPV 30.9% 21.9% 41.1%
NPV 93.4% 85.3% 97.8%
in the previous evaluation of the Widal test in Kathmandu
(58 and 51% for the anti-H and anti-O responses, respectively)
(Adhikari et al., 2015), but lower than that reported for Tubex
TF and Typhidot rapid diagnostic tests, the specificity for
which are reported to be between ∼60 and 90%, depending
on the population studied (Keddy et al., 2011; Thriemer et al.,
2013).
The findings of this evaluation are likely applicable to a wide
variety of resource-limited settings, and reflect a “real-world”
situation inmany tropical healthcare settings. The difficulty of the
task in accurately detecting patients with enteric fever etiology in
our ALS evaluation cohort is demonstrated by comparison with
that of the parent treatment study (Arjyal et al., 2016). In terms
of performing the ALS assay in other similar facilities in endemic
regions, the training of local dedicated staff was uncomplicated
and the logistic requirements were relatively minimal. Some basic
laboratory infrastructure was required, including an incubator,
centrifuge, ELISA plate reader and reagents for performing
PBMC separation. On-going work is attempting to address these
requirements to make the assay more amenable to widespread
use; this includes simplifying the PBMC isolation procedure,
removing the need for a specific CO2 incubator and using a lateral
flow-device rather than ELISA method for antibody detection
(Khanam et al., 2013). ALS responses appear to be robust and
durable for at least 7 days after hospital presentation, suggesting
that only a single sample within this time period is required.
While further work is required to detail the resolution of these
responses over time, titers appeared to normalize by 3 months
after presentation suggesting that they are able to detect acute
infection and are not affected by the development of exposure-
related immunity.
Our data revealed several useful insights into the likely
underlying disease etiology in patients presenting with non-
specific febrile disease in an endemic region. It was likely that
many of the patients recruited to the study in Nepal had enteric
fever as the true underlying cause of their presentation but that
due to the constraints of blood culture this was not detected.
This was supported by evaluation of the clinical characteristics of
high-low responders in which only ∼50% of those participants
with clinically compatible signs and symptoms and high ALS
responses were blood culture confirmed cases. This also suggests
that the specificity of the assay is likely to be considerably higher
than that estimated by our study; further work is ongoing to
determine the true etiological cause of fever in these study
participants by excluding other common local febrile illnesses
(Thompson et al., 2015). In high burden endemic settings,
the high negative predictive value of the assay could be used
to exclude enteric fever in febrile individuals presenting to
hospital. In settings where the etiology is more likely to be
mixed, incorporation of rapid diagnostic tests for malaria and
dengue would also need to be considered; Kathmandu has a
low incidence of both of these conditions, although rickettsial
infections are frequent (Thompson et al., 2015). An alternative
strategy could be to investigate the performance of ALS responses
to malaria, dengue or rickettsial antigens as has been performed
with tuberculosis and pneumococcal infection (Jiao et al., 2015).
In conclusion, we have evaluated and characterized the
performance of an ALS assay for the detection of typhoid
or paratyphoid infection in two human challenge models
and translated and evaluated the diagnostic performance in
a high incidence endemic setting. Although not currently
adapted for use outside of the clinical research setting in
resource-limited settings, the anti-MP IgA ALS assay offers
good sensitivity for detecting cases of typhoid/paratyphoid over
existing serological approaches and could double enteric fever
disease burden estimates over those provided by blood culture
data alone. Further work is needed to evaluate alternative,
improved reference standards, to optimize antigen selection
and to compare ALS responses with other currently available
alternative diagnostic methods including the rapid serological
diagnostic tests.
AUTHOR CONTRIBUTIONS
TD and AP designed the studies and acquired the funding. TD,
CJ, CB, CW, and MG performed the CHIM studies, acquired
the samples, and performed the assays. CJ, SD, RS, MS, AK,
and AA transferred the assays and performed sample collection
and diagnostic assays in Nepal with oversight and active input
from BB and SB. TD, CB, and MV performed the data analysis.
The data were curated by SB, AK, CJ, and TD. Manuscript
was prepared by TD with support from MV and subsequently
reviewed with input by all authors.
FUNDING
This work was generously supported by the Bill and Melinda
Gates Foundation (Global Health grant number OPP1089317).
Additional funding for the challenge studies was provided
by a Wellcome Trust Strategic Translational Award (grant
number 092661 to AP; www.wellcome.ac.uk); the European
Vaccine Initiative (ref: PIM); and the NIHR Oxford Biomedical
Research Centre (Clinical Research Fellowships to TD and CW;
Frontiers in Microbiology | www.frontiersin.org 11 October 2017 | Volume 8 | Article 2031
Darton et al. ALS Diagnostics for Enteric Fever
oxfordbrc.nihr.ac.uk). TD, CJ, CB, CW, AP are supported by the
NIHR Oxford Biomedical Research Centre (Oxford University
Hospitals NHS Trust, Oxford); CB is a Marie Curie Research
Fellow supported by the European Union (FP7); SB is a Sir Henry
Dale Fellow, jointly funded by the Wellcome Trust and the Royal
Society (100087/Z/12/Z); AP is a Jenner Investigator and James
Martin Senior Fellow; TD is an NIHR funded Academic Clinical
Lecturer.
ACKNOWLEDGMENTS
We gratefully acknowledge the assistance of the participants
who have taken part in the study both in Oxford and
Nepal. We are also grateful for the support from Dr. Laura
B. Martin and GSK Vaccines for Global Health for setting
up the paratyphoid challenge model and providing the S.
Paratyphi O:2 antigen and the S. Paratyphi challenge strain.
We also gratefully acknowledge the assistance of Dr. Raphael
Simon in producing the purified flagellin antigen used in our
assays.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2017.02031/full#supplementary-material
REFERENCES
Adhikari, A., Rauniyar, R., Raut, P. P., Manandhar, K. D., and Gupta, B. P.
(2015). Evaluation of sensitivity and specificity of ELISA against Widal test
for typhoid diagnosis in endemic population of Kathmandu. BMC Infect. Dis.
15:523. doi: 10.1186/s12879-015-1248-6
Arjyal, A., Basnyat, B., Nhan, H. T., Koirala, S., Giri, A., Joshi, N., et al. (2016).
Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an
open-label, two-centre, randomised controlled trial. Lancet Infect. Dis. 16,
535–545. doi: 10.1016/S1473-3099(15)00530-7
Baker, S., Favorov, M., and Dougan, G. (2010). Searching for the elusive typhoid
diagnostic. BMC Infect. Dis. 10:45. doi: 10.1186/1471-2334-10-45
Buckle, G. C.,Walker, C. L., and Black, R. E. (2012). Typhoid fever and paratyphoid
fever: systematic review to estimate global morbidity and mortality for 2010. J.
Glob. Health 2:10401. doi: 10.7189/jogh.01.010401
Carstensen, B., Gurrin, L., Ekstrom, C., and Figurski, M. (2013). MethComp:
Functions for Analysis of Agreement in Method Comparison Studies. R Package
version 1.22. Available online at: http://cran.r-project.org/package=MethComp
(Accessed on August 08, 2016).
Chang, H. S., and Sack, D. A. (2001). Development of a novel in vitro
assay (ALS assay) for evaluation of vaccine-induced antibody secretion from
circulating mucosal lymphocytes. Clin. Diagn. Lab. Immunol. 8, 482–488.
doi: 10.1128/CDLI.8.3.482-488.2001
Chappuis, F., Alirol, E., d’Acremont, V., Bottieau, E., and Yansouni, C. P. (2013).
Rapid diagnostic tests for non-malarial febrile illness in the tropics. Clin.
Microbiol. Infect. 19, 422–431. doi: 10.1111/1469-0691.12154
Crump, J. A., Sjolund-Karlsson, M., Gordon, M. A., and Parry, C. M.
(2015). Epidemiology, clinical presentation, laboratory diagnosis,
antimicrobial resistance, and antimicrobial management of invasive
Salmonella infections. Clin. Microbiol. Rev. 28, 901–937. doi: 10.1128/CMR.
00002-15
Darton, T. C., Blohmke, C. J., and Pollard, A. J. (2014). Typhoid epidemiology,
diagnostics and the human challenge model. Curr. Opin. Gastroenterol. 30,
7–17. doi: 10.1097/MOG.0000000000000021
Dewan, A. M., Corner, R., Hashizume, M., and Ongee, E. T. (2013). Typhoid fever
and its association with environmental factors in the Dhaka Metropolitan Area
of Bangladesh: a spatial and time-series approach. PLoSNegl. Trop. Dis. 7:e1998.
doi: 10.1371/journal.pntd.0001998
Garcia-Gomez, E., Gonzalez-Pedrajo, B., and Camacho-Arroyo, I. (2013). Role
of sex steroid hormones in bacterial-host interactions. Biomed. Res. Int.
2013:928290. doi: 10.1155/2013/928290
Giavarina, D. (2015). Understanding Bland Altman analysis. Biochem. Med.
(Zagreb) 25, 141–151. doi: 10.11613/BM.2015.015
Health Protection Agency (2013). Investigation of blood cultures (for organisms
other than Mycobacterium species. UK Standards for Microbiological
Investigations.
Islam, K., Sayeed, M. A., Hossen, E., Khanam, F., Charles, R. C., Andrews,
J., et al. (2016). Comparison of the performance of the TPTest, Tubex,
Typhidot and Widal immunodiagnostic assays and blood cultures in
detecting patients with typhoid fever in Bangladesh, including using a
Bayesian latent class modeling approach. PLoS Negl. Trop. Dis. 10:e0004558.
doi: 10.1371/journal.pntd.0004558
Jiao, J.,Wang,M. S., Yang, X. G., andWang, X. F. (2015). Evaluation of ALS assay of
TB-SA for diagnosis of pulmonary tuberculosis. J. Immunoassay Immunochem.
36, 119–127. doi: 10.1080/15321819.2014.908127
Karkey, A., Arjyal, A., Anders, K. L., Boni, M. F., Dongol, S., Koirala, S.,
et al. (2010). The burden and characteristics of enteric fever at a healthcare
facility in a densely populated area of Kathmandu. PLoS ONE 5:e13988.
doi: 10.1371/journal.pone.0013988
Karkey, A., Jombart, T., Walker, A. W., Thompson, C. N., Torres, A., Dongol, S.,
et al. (2016). The ecological dynamics of fecal contamination and Salmonella
typhi and Salmonella paratyphi A in municipal Kathmandu drinking water.
PLoS Negl. Trop. Dis. 10:e0004346. doi: 10.1371/journal.pntd.0004346
Karkey, A., Thompson, C. N., Tran Vu Thieu, N., Dongol, S., Le Thi Phuong, T.,
Voong Vinh, P., et al. (2013). Differential epidemiology of Salmonella typhi
and paratyphi A in Kathmandu, Nepal: a matched case control investigation
in a highly endemic enteric fever setting. PLoS Negl. Trop. Dis. 7:e2391.
doi: 10.1371/journal.pntd.0002391
Keddy, K. H., Sooka, A., Letsoalo,M. E., Hoyland, G., Chaignat, C. L., Morrissey, A.
B., et al. (2011). Sensitivity and specificity of typhoid fever rapid antibody tests
for laboratory diagnosis at two sub-Saharan African sites. Bull. World Health
Organ. 89, 640–647. doi: 10.2471/BLT.11.087627
Khanam, F., Sheikh, A., Sayeed, A., Bhuiyan, S., Choudhury, F. K., Salma,
U., et al. (2013). Evaluation of a typhoid/paratyphoid diagnostic assay
(TPTest) detecting anti-Salmonella IgA in secretions of peripheral blood
lymphocytes in patients in Dhaka, Bangladesh. PLoS Negl. Trop. Dis. 7:e2316.
doi: 10.1371/journal.pntd.0002316
Kirkpatrick, B. D., Bentley, M. D., Thern, A. M., Larsson, C. J., Ventrone, C.,
Sreenivasan, M. V., et al. (2005). Comparison of the antibodies in lymphocyte
supernatant and antibody-secreting cell assays for measuring intestinal
mucosal immune response to a novel oral typhoid vaccine (M01ZH09).
Clin. Diagn. Lab. Immunol. 12, 1127–1129. doi: 10.1128/CDLI.12.9.1127-112
9.2005
McCullagh, D., Dobinson, H. C., Darton, T., Campbell, D., Jones, C., Snape,
M., et al. (2015). Understanding paratyphoid infection: study protocol
for the development of a human model of Salmonella enterica serovar
Paratyphi A challenge in healthy adult volunteers. BMJ Open 5:e007481.
doi: 10.1136/bmjopen-2014-007481
Metz, C. E. (1978). Basic principles of ROC analysis. Semin. Nucl. Med. 8, 283–298.
doi: 10.1016/S0001-2998(78)80014-2
Parry, C. M., Wijedoru, L., Arjyal, A., and Baker, S. (2011). The utility of diagnostic
tests for enteric fever in endemic locations. Expert Rev. Anti. Infect. Ther. 9,
711–725. doi: 10.1586/eri.11.47
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., et al.
(2011). pROC: an open-source package for R and S+ to analyze and compare
ROC curves. BMC Bioinformatics 12:77. doi: 10.1186/1471-2105-12-77
Sheikh, A., Bhuiyan, M. S., Khanam, F., Chowdhury, F., Saha, A., Ahmed, D., et al.
(2009). Salmonella enterica serovar Typhi-specific immunoglobulin A antibody
Frontiers in Microbiology | www.frontiersin.org 12 October 2017 | Volume 8 | Article 2031
Darton et al. ALS Diagnostics for Enteric Fever
responses in plasma and antibody in lymphocyte supernatant specimens in
Bangladeshi patients with suspected typhoid fever. Clin. Vaccine Immunol. 16,
1587–1594. doi: 10.1128/CVI.00311-09
Storey, H. L., Huang, Y., Crudder, C., Golden, A., de los Santos, T., and
Hawkins, K. (2015). A meta-analysis of typhoid diagnostic accuracy studies:
a recommendation to adopt a standardized composite reference. PLoS ONE
10:e0142364. doi: 10.1371/journal.pone.0142364
Thompson, C. N., Blacksell, S. D., Paris, D. H., Arjyal, A., Karkey, A., Dongol, S.,
et al. (2015). Undifferentiated febrile illness in Kathmandu, Nepal. Am. J. Trop.
Med. Hyg. 92, 875–878. doi: 10.4269/ajtmh.14-0709
Thriemer, K., Ley, B., Menten, J., Jacobs, J., and van den Ende, J. (2013). A
systematic review and meta-analysis of the performance of two point of care
typhoid fever tests, Tubex TF and Typhidot, in endemic countries. PLoS ONE
8:e81263. doi: 10.1371/journal.pone.0081263
Waddington, C. S., Darton, T. C., Jones, C., Haworth, K., Peters, A., John, T.,
et al. (2014). An outpatient, ambulant-design, controlled human infection
model using escalating doses of Salmonella Typhi challenge delivered in sodium
bicarbonate solution. Clin. Infect. Dis. 58, 1230–1240. doi: 10.1093/cid/ciu078
Wain, J., Diep, T. S., Ho, V. A., Walsh, A. M., Hoa, N. T. T., Parry, C. M.,
et al. (1998). Quantitation of bacteria in blood of typhoid fever patients
and relationship between counts and clinical features, transmissibility, and
antibiotic resistance. J. Clin. Microbiol. 36, 1683–1687.
Wain, J., Hendriksen, R. S., Mikoleit, M. L., Keddy, K. H., and Ochiai, R. L.
(2015). Typhoid fever. Lancet 385, 1136–1145. doi: 10.1016/S0140-6736(13)
62708-7
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer EB and handling Editor declared their shared affiliation.
Copyright © 2017 Darton, Jones, Dongol, Voysey, Blohmke, Shrestha, Karkey,
Shakya, Arjyal, Waddington, Gibani, Carter, Basnyat, Baker and Pollard. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Microbiology | www.frontiersin.org 13 October 2017 | Volume 8 | Article 2031
